Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3117 in patients with advanced malignant cancer
NCT06415903Phase 1Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3117 in malignant neoplasm, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicity, Maximum Tolerated Dose and 1 more. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
TQB3117
03
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT06415903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06415903.